Royalty Pharma earnings highlight mixed quarterly picture

Royalty Pharma (RPRX) reported second quarter 2026 results with revenue of US$674.14 million and net income of US$17.88 million. The six-month figures showed higher revenue and net income compared with the same period a year earlier.

Royalty Pharma's share price has risen strongly with a year to date share price return of 48.71%, while the 1 year total shareholder return of 64.61% points to solid longer term momentum despite a modest 1 day pullback.

If earnings news has you looking beyond a single stock, this is a good moment to scan for other opportunities in biopharma and related research using the 43 healthcare AI stocks

After Royalty Pharma's strong share price move and a mixed quarterly earnings picture, the balance between upside potential and earnings risk looks less straightforward. The key question is whether the current valuation still leaves enough reward on the table for new buyers.

Most Popular Narrative: 2.5% Undervalued

Royalty Pharma's most followed narrative places fair value at $59.25, only slightly above the last close of $57.79, which frames the current share price as close to that narrative target while still suggesting some upside based on modeled cash flows and earnings power.

The robust scientific pipeline, driven by advancements in biologics, gene therapies, and next-generation medicines like daraxonrasib, creates high-value assets that can enter into blockbuster status. Participation in these early, high-impact assets (as in the Revolution Medicines deal) positions Royalty Pharma for long-duration, high-growth royalty streams, directly benefitting long-term revenue and earnings.

Want to see what sits behind that fair value for Royalty Pharma? The narrative leans on faster revenue expansion, a step change in profitability, and a sharply lower future earnings multiple. Curious how those pieces fit together into one valuation story.

Result: Fair Value of $59.25 (UNDERVALUED)

However, the Royalty Pharma story also carries real execution risk, including the Vertex Alyftrek royalty dispute and rising competition for new royalty deals that could pressure future economics.

Another view on Royalty Pharma's valuation

The Simply Wall St DCF model presents a very different picture for Royalty Pharma. In this view, the stock at $57.79 is trading well below an estimated future cash flow value of $195.31, which points to a very large implied discount. That gap raises a clear question: is the model too optimistic, or is the market too cautious right now?

Next Steps

Given the mix of positives and concerns around Royalty Pharma, it may be helpful to move quickly and assess the full picture yourself. Start with the 2 key rewards and 3 important warning signs.

Looking for more Royalty Pharma style investment ideas?

If Royalty Pharma has your attention, do not stop here. Broaden your watchlist now or risk missing other opportunities sitting in plain sight.

• Target potential mispricing by scanning the market for companies that look attractively valued using the 49 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies that offer robust yields through the 8 dividend fortresses.
• Put capital to work in companies with resilient finances and solid fundamentals by checking the solid balance sheet and fundamentals stocks screener (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.